39910608|t|Carvacrol attenuated haloperidol-induced Parkinson's disease via TNF/NFkappabeta-NLRP3-mediated pyroptosis.
39910608|a|BACKGROUND: Parkinson's disease is a debilitating and the second most common neurodegenerative disorder with a high prevalence. Parkinson's disease has a multifaceted etiology characterized by an altered redox state and an excessive inflammatory response. In this study, we investigated the potential neuroprotective properties of carvacrol in a haloperidol-induced Parkinson's model. In female Sprague-Dawley rats, the animal Parkinson model was induced by intraperitoneally administering 1 mg / kg of haloperidol once daily for fifteen days. Carvacrol was administered at a dose of 25 and 50 mg / kg once daily for fifteen days before haloperidol administration. In order to further illustrate the vital role of the tumor necrosis factor (TNF-alpha) pathway, we administered 50 mg / kg of the TNF-alpha inhibitor thalidomide once daily for 15 days. RESULTS: Our results showed that haloperidol-induced motor deficits, changed endogenous antioxidant enzymes, along with higher levels of inflammasome (NLRP3) and other inflammatory mediators. Moreover, increased levels of lipid peroxidase (LPO) indicated a significant rise in oxidative stress due to haloperidol. Moreover, carvacrol reduced these effects by preventing pyroptosis mediated by the inflammasome (NLRP3) and TNF-alpha. The administration of thalidomide mitigated oxidative stress and suppresses inflammatory pathways through the augmentation of the intrinsic antioxidant system. Further, co-treatment of carvacrol with thalidomide synergized the neuroprotective effect of carvacrol as demonstrated by various immunoassays and histology analyses. CONCLUSIONS: Taken together, our findings suggest that carvacrol mitigated haloperidol-induced Parkinson-like symptoms, partially through the downregulation of TNF-alpha and NLRP3.
39910608	0	9	Carvacrol	Chemical	MESH:C073316
39910608	21	32	haloperidol	Chemical	MESH:D006220
39910608	41	60	Parkinson's disease	Disease	MESH:D010300
39910608	65	68	TNF	Gene	24835
39910608	81	86	NLRP3	Gene	287362
39910608	120	139	Parkinson's disease	Disease	MESH:D010300
39910608	185	211	neurodegenerative disorder	Disease	MESH:D019636
39910608	236	255	Parkinson's disease	Disease	MESH:D010300
39910608	341	353	inflammatory	Disease	MESH:D007249
39910608	439	448	carvacrol	Chemical	MESH:C073316
39910608	454	465	haloperidol	Chemical	MESH:D006220
39910608	474	485	Parkinson's	Disease	MESH:D010300
39910608	518	522	rats	Species	10116
39910608	535	544	Parkinson	Disease	MESH:D010302
39910608	611	622	haloperidol	Chemical	MESH:D006220
39910608	652	661	Carvacrol	Chemical	MESH:C073316
39910608	745	756	haloperidol	Chemical	MESH:D006220
39910608	826	847	tumor necrosis factor	Gene	103694380
39910608	849	858	TNF-alpha	Gene	24835
39910608	903	912	TNF-alpha	Gene	24835
39910608	923	934	thalidomide	Chemical	MESH:D013792
39910608	992	1003	haloperidol	Chemical	MESH:D006220
39910608	1012	1026	motor deficits	Disease	MESH:D009461
39910608	1110	1115	NLRP3	Gene	287362
39910608	1127	1139	inflammatory	Disease	MESH:D007249
39910608	1181	1197	lipid peroxidase	Gene	287610
39910608	1199	1202	LPO	Gene	287610
39910608	1260	1271	haloperidol	Chemical	MESH:D006220
39910608	1283	1292	carvacrol	Chemical	MESH:C073316
39910608	1370	1375	NLRP3	Gene	287362
39910608	1381	1390	TNF-alpha	Gene	24835
39910608	1414	1425	thalidomide	Chemical	MESH:D013792
39910608	1468	1480	inflammatory	Disease	MESH:D007249
39910608	1577	1586	carvacrol	Chemical	MESH:C073316
39910608	1592	1603	thalidomide	Chemical	MESH:D013792
39910608	1645	1654	carvacrol	Chemical	MESH:C073316
39910608	1774	1783	carvacrol	Chemical	MESH:C073316
39910608	1794	1805	haloperidol	Chemical	MESH:D006220
39910608	1814	1837	Parkinson-like symptoms	Disease	MESH:D010302
39910608	1879	1888	TNF-alpha	Gene	24835
39910608	1893	1898	NLRP3	Gene	287362
39910608	Positive_Correlation	MESH:D006220	287362
39910608	Positive_Correlation	MESH:D006220	MESH:D007249
39910608	Negative_Correlation	MESH:D013792	MESH:D007249
39910608	Negative_Correlation	MESH:C073316	24835
39910608	Negative_Correlation	MESH:C073316	287610
39910608	Positive_Correlation	MESH:D006220	MESH:D010300
39910608	Negative_Correlation	MESH:C073316	287362
39910608	Positive_Correlation	MESH:D006220	MESH:D009461
39910608	Positive_Correlation	MESH:D006220	287610
39910608	Negative_Correlation	MESH:C073316	MESH:D010302
39910608	Cotreatment	MESH:C073316	MESH:D013792
39910608	Negative_Correlation	MESH:C073316	MESH:D006220
39910608	Negative_Correlation	MESH:C073316	MESH:D010300
39910608	Positive_Correlation	MESH:D006220	MESH:D010302
39910608	Negative_Correlation	MESH:D013792	24835

